Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial—Correction | JAMA Neurology | JAMA Network
[Skip to Navigation]
Sign In
Correction
May 2004

Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial—Correction

Arch Neurol. 2004;61(5):776. doi:10.1001/archneur.61.5.776

Error in Author Contributions. In the Original Contribution by Ritchie et al titled "Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial," published in the December 2003 issue of the ARCHIVES (2003;60:1685-1691), an error occurred in the paragraph listing author contributions on page 1691. The contributions of Drs Bush and Tanzi were limited solely to study design and concept, and to consultation on biochemistry. The journal regrets the error.

×